Conrad En Zuo Chan

Title: The Innovations of Conrad En Zuo Chan

Introduction

Conrad En Zuo Chan is a notable inventor based in Singapore, recognized for his contributions to the field of biotechnology. His work primarily focuses on the development of antigen binding proteins that target pathogenic mycobacteria. With a single patent to his name, Chan has made significant strides in understanding and combating infectious diseases.

Latest Patents

Chan's most recent patent is titled "Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins." This patent describes antigen binding proteins that specifically bind to pathogenic mycobacteria-derived Mannose-Capped Lipoarabinomannan (ManLAM). The patent outlines methods and kits for utilizing and producing these antigen binding proteins. Additionally, it details proteins that target the alpha 1-2 linkage mannose caps of ManLAM, as well as those that bind to LAM with a mannose sugar capping motif. This innovation has the potential to enhance diagnostic and therapeutic approaches in infectious disease management.

Career Highlights

Throughout his career, Chan has worked with esteemed institutions such as the National University of Singapore and DSO National Laboratories. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Some of Chan's notable coworkers include Paul Macary and Brendon John Hanson. Their collaborative efforts have further advanced the research and development of innovative solutions in biotechnology.

Conclusion

Conrad En Zuo Chan's work exemplifies the impact of innovative research in the field of biotechnology. His patent on antigen binding proteins represents a significant advancement in the fight against infectious diseases.